Richarda Kayne News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Richarda kayne. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Richarda Kayne Today - Breaking & Trending Today
Shares of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR – Free Report) are going to reverse split before the market opens on Monday, January 8th. The 1-30 reverse split was announced on Monday, January 8th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, January 8th. Eiger BioPharmaceuticals Trading Down 5.2 […] ....
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR – Get Free Report) saw a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 1,070,000 shares, a drop of 7.0% from the November 30th total of 1,150,000 shares. Based on an average daily trading volume, of 301,300 shares, the short-interest […] ....
StockNews.com assumed coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR – Free Report) in a research report report published on Tuesday morning. The brokerage issued a sell rating on the biotechnology company’s stock. Separately, Citigroup lowered their target price on shares of Eiger BioPharmaceuticals from $4.00 to $3.00 and set a buy rating for the company […] ....
Eiger BioPharmaceuticals (NASDAQ:EIGR) Stock Crosses Below 50-Day Moving Average of $0.30 themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
StockNews.com started coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR – Free Report) in a research report sent to investors on Sunday morning. The firm issued a sell rating on the biotechnology company’s stock. Separately, Citigroup lowered their price target on shares of Eiger BioPharmaceuticals from $4.00 to $3.00 and set a buy rating on the […] ....